LGDN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Royalty-model ProfitabilityLigand’s licensing and royalty model supports very high margins because partners carry much of the development and commercial infrastructure. This capital-efficient structure can convert growing partner sales into durable operating profit and cash generation over the next several quarters.
Expanded Royalty PortfolioThe XOMA acquisition materially broadens Ligand’s asset base and increases exposure to commercial and late-stage products. Greater portfolio depth and longer royalty duration can reduce reliance on individual programs while creating multiple avenues for sustained royalty and milestone growth.
Partnered Revenue MomentumStrong royalty growth from multiple partnered products demonstrates that Ligand’s portfolio is producing meaningful commercial traction. Continued adoption of partner medicines can provide an expanding revenue base without requiring Ligand to build a large direct sales organization.
Bears Say
Higher LeverageDebt now exceeds equity after a meaningful increase in leverage, raising financial risk compared with Ligand’s historically more conservative profile. Although current cash generation is strong, higher obligations can constrain acquisition capacity and reduce resilience if earnings or royalties normalize lower.
Volatile Cash ConversionHealthy current operating and free cash flow is tempered by a history of substantial variability, showing that cash conversion is not consistently predictable. Such swings can complicate capital planning and make funding acquisitions or obligations more dependent on the timing of partner payments.
Clinical And Regulatory Execution RiskLigand’s expanded development portfolio offers upside but remains exposed to binary clinical outcomes across several pivotal programs. Failed readouts or delays could reduce milestone receipts, postpone future royalties, and weaken the expected economic contribution from assets not yet commercially validated.
Ligand Pharma News
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
Currently, no data Available
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is CHF5.17B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Aug 06, 2026. The company reported CHF1.946 earnings per share for the quarter, beating the consensus estimate of CHF1.65 by CHF0.296.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma does not currently pay dividends.
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.91.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,935,610 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of CHF1.946 in its last earnings report, beating expectations of CHF1.65. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in CH:LGDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF298.96 (― Upside)
CHF298.96 (― Upside)
Blogger Sentiment
Bullish
CH:LGDN Sentiment 63%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.87%
12-Months-Change
Fundamentals
Return on Equity
20.06%
Trailing 12-Months
Asset Growth
130.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGDN Company Deck
LGDN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust top-line and EPS growth, significant cash flow generation, completion of an accretive and scalable acquisition (XOMA), and successful low-cost financing that materially strengthens capital flexibility. Manageable near-term challenges include a product sales decline (Kyprolis), one-time charges, accounting complexity from increased financial royalty assets, and some timing risk from an FDA recommendation requiring a Phase III for PSC. On balance, the company presented multiple clear growth drivers and disciplined capital deployment that outweigh the identified risks.View all CH:LGDN earnings summariesLGDN Stock 12 Month Forecast
Average Price Target
―Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Xencor
―
Zymeworks
―
AbCellera Biologics
―